Tybourne Capital Management (HK)
Long / Short- Manager
- Tybourne Capital Management (HK)
- Quarter
- Q3 2025
- Filed
- 2025-11-06
- 13F value
- $30.9M
- Positions
- 4
- CIK
- 0001553936
StaleLatest 13F is 3 quarters old — this filer may be inactive or wound down. Figures reflect Q3 2025 and are excluded from the Market Overview.
Weights are % of 13F book — no reported capital figure for this filer.i
| # | # Shares | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Taysha Gene Therapies Inc (tsha US)TSHAHISTORY | 39.11% | (9.6%) | $12.1M | 3,700,000 | (395,000) | 1.14% | 13F |
| 2 | Forte Biosciences Inc (fbrx US)34962G208HISTORY | 38.15% | — | $11.8M | 786,647 | — | 9.99% | 13F13G (older) |
| 3 | Alumis Inc (alms US)ALMSHISTORY | 18.05% | — | $5.6M | 1,399,250 | — | 1.11% | 13F |
| 4 | Zentalis Pharmaceuticals Inc (zntl US)ZNTLHISTORY | 4.69% | (35.0%) | $1.5M | 961,486 | (516,666) | 1.34% | 13F |
Positions are from the latest 13F-HR (period end 2025-09-30). Weights are calculated: position value ÷ the 13F book. Rows marked Off-13F are >5% stakes disclosed on a Schedule 13D/13G dated after the latest 13F; they report shares and percent of class but no dollar value. Chg Shares and % Chg compare with the adjacent prior quarter's 13F only. % Out is either calculated (position shares ÷ issuer shares outstanding from the issuer's XBRL cover page; weighted-average basic shares as a fallback) or reported (percent of class on a Schedule 13D/13G newer than the 13F period) — hover a value for its source and date. Unavailable figures show “—”, never an estimate. Methodology